Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer

Fig. 2

Combined inhibition of PI3K and EGFR synergistically inhibits BLBC cell growth via induction of apoptosis. The growth of the basal-like HCC70 (a) or SUM149 (d) cells was assessed after 4 days of treatment with single agent or combination treatment with LY294002 and gefitinib at the indicated concentrations. The results are shown as luminescence of viable cells. b Combination index plot for 5 or 10 μM LY294002 combined with 0.5, 1, 2, 4, 8, or 10 μM gefitinib (HCC70) or 0.5, 1, 2, 4 μM gefitinib (SUM149). c Dose-dependent induction of apoptosis in HCC70 cells by gefitinib and LY294002

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us